TrialClinical and translational science2022

Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS-1211, a tissue-nonspecific alkaline phosphatase inhibitor.

Sonomi Maruyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.